The contemporary management of prostate cancer
- PMID: 40572035
- DOI: 10.3322/caac.70020
The contemporary management of prostate cancer
Abstract
Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image-guided hypofractionated and stereotactic radiotherapy, novel anti-androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
Keywords: medical oncology; prostate neoplasms; radiation oncology; survivorship; urology.
© 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
References
REFERENCES
-
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229‐263. doi:10.3322/caac.21834
-
- Bray F, Colombet M, Aitken JF, et al., eds. Cancer Incidence in Five Continents Vol. XII (IARC CancerBase No. 19). International Agency for Research on Cancer; 2023. Accessed December 4, 2024, https://ci5.iarc.who.int/
-
- Chen R, Ren S, Yiu MK, et al. Prostate cancer in Asia: a collaborative report. Asian J Urol. 2014;1:15‐29. doi:10.1016/j.ajur.2014.08.007
-
- Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524‐531. doi:10.1111/iju.13593
-
- James ND, Tannock I, N’Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683‐1722. doi:10.1016/s0140‐6736(24)00651‐2
Publication types
LinkOut - more resources
Full Text Sources